Serial cytokine changes in peritoneal effluent and plasma during peritonitis in patients on continuous ambulatory peritoneal dialysis (CAPD)

Inflammation Research

Volumn 46, Issue 4, 1997, Pages 132-136

  Koziol Montewka M ^a   Ksiazek A ^a   Janicka, L ^a   Baranowicz, I ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Acute phase proteins; Cellular infiltration; Cytokines; Local inflammation; Peritoneal dialysis

Indexed keywords

ANTIBIOTIC AGENT; CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; PERITONEAL DIALYSIS FLUID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY DISEASE; LYMPHOCYTIC INFILTRATION; MESOTHELIUM CELL; PERITONITIS; STATISTICAL ANALYSIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ASCITIC FLUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-2; INTERLEUKIN-6; INTERLEUKIN-8; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONITIS; RECEPTORS, INTERLEUKIN-2; REGRESSION ANALYSIS;

EID: 0030887617     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050536     Document Type: Article

References (31)

1. Glancey GR, Cameron JS, Ogg CS. Peritoneal drainage: an important element in host defence against staphylococcal peritonitis in patients on CAPD. Nephrol Dial Transplant 1992;7:627-31.
2. Keane WF, Komty CM, Verbrugh HA, Peterson PK. Opsonic deficiency of peritoneal dialysis effluent in continuous ambulatory peritoneal dialysis. Kidney Int 1984;25:539-43
3. Lamperi S, Carozzi S. Detective opsonic activity of peritoneal effluent during continuous ambulatory peritoneal dialysis (CAPD): Importance and prevention. Peril Dial Bull 1986;6:87-92.
4. Lamperi S, Carozzi S. Immunologic patterns in CAPD patients with peritonitis. Clin Nephrol 1988;30 (Suppl 1): S41-54.
5. Betjes MGH, Tuk CW, Struijk DG, Krediet RT, Arisz L, Hoefsmit ECM, et al. Immuno-effector characteristics of peritoneal cells during CAPD treatment: a longitudinal study. Kidney Int 1993;43:641-8.
6. Davies SJ, Suassuna J, Ogg CS, Cameron JS. Activation of immunocompetent cells in the peritoneum of patients treated with CAPD. Kidney Int 1989;36:661-8.
7. Topley N, Mackenzie R, Jörres A, Coles GA, Davies M, Williams JD. Cytokine networks in continuous ambulatory peritoneal dialysis: interactions of resident cells during inflammation in the peritoneal cavity. Perit Dial Int 1993;13 (Suppl 2): S282-5
8. Levis SL, Holmes CJ. Host denense mechanisms involved in peritonitis. Pent Dial Int 1993;13 (Suppl 2): S295-S298.
9. Topley N, Jörres A, Luttmann W, Petersen MM, Lang MJ, Thierauch KH, et al. Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1β and TNFα. Kidney Int 1993;43:226-33.
10. Brulez HFH, Verbrugh HA. First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Perit Dial Int 1995;15:S24-34.
11. Bourikas GK, Vargemezis V, Dalla V, Ritis K, Alexopoulos G, Pasadakis P, et al. T cell subpopulations in peritoneal fluid in CAPD patients. In: Ota K, Maher J, Winchester J, Hirszel P, editors. Current concepts in peritoneal dialysis. Excerpta Medica, 1992:262-5.
12. Suassuna JHR, Neves FC, Glancey G, Ogg CS, Hartley RB, Cameron JS. Activation markers on leukocytes within the peritoneal membrane of continuous ambulatory peritoneal dialysis (CAPD) patients. In: Ota K, Maher J, Winchester J, Hirszel P, editors. Current concepts in peritoneal dialysis. Excerpta Medica, 1992:283-91.
13. Levis SL, Kutvirt SG, Cooper CL, Bonner PN, Holmes CJ. Characteristics of peripheral and peritoneal lymphocytes from continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1993;13 (Suppl 2): S273-7.
14. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: Biology, function and clinical application. Ann Inter Med 1990;113:619-27.
15. Gerez L, Madar L, Shkolnik T, Kristal B, Arad G, Reshef A, et al. Regulation of interleukin-2 and interferon-γ expression in renal failure. Kidney Int 1991;40:266-72
16. Donati D, Degiannis D, Homer L, Gastali L, Raskova J, Raska Jr. Immune deficiency in uremia: Interleukin 2 production and responsiveness and interleukin-2 receptor expression and release. Nephron 1991;58:268-75.
17. Walz G, Kunzendorf U, Josimovic-Alasevic O, Preuschoff L, Schwarz A, Keller F, et al. Soluble interleukin 2 receptor and tissue polypeptide antigen serum concentrations in end-stage renal failure. Nephron 1990;56:157-61.
18. Carrosi S, Lamperi S. Peritonitis prevention in CAPD. Clin Nephrol 1988;30 (Suppl. 1):S45-8.
19. Zemel D, Betjes MGH, Dinkla C, Struijk DG, Krediet RT. Analysis of inflammmatory mediators and peritoneal permeability to macromolecules shortly before the onset of overt peritonitis in patients treated with CAPD. Perit Dial Int 1995;15:131-41.
20. Lin CY, Lin CC, Huang TP. Serial changes of interleukin-6 and interleukin-8 levels in drain dialysate of uremic patients with continuous ambulatory peritoneal dialysis during peritonitis. Nephron 1993;63:404-8.
21. Goldman M, Vandenabeele P, Moulart J, Amraoui Z, Abramowicz D, Nortier J, et al. Intraperitoneal secretion of interleukin-6 during continuous ambulatory peritoneal dialysis. Nephron 1990; 56:277-80.
22. Zemel D, Krediet RT, Koomen GCM, Kortekaas WMR, Geertzen HGM, Berge RJM. Interleukin-8 during peritonitis in patients treated with CAPD; an in-vivo model of acute inflammation. Nephrol Dial Transplant 1994;9:169-74.
23. Lee HH, Carlson RW, Bull DM. Early diagnosis of spontaneous bacterial peritonitis: values of ascitic fluid variables. Infection 1987;15:232-6.
24. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994;15:81-7.
25. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80.
26. Hasbargen JA, Hasbargen BJ, Lockard JW Butler CE. The utility of C-reactive protein (CRP) measurement in patients on continuous ambulatory peritoneal dialysis (CAPD) with peritonitis. In: Ota K, Maher J, Winchester J, Hirszel P editors. Current concepts in peritoneal dialysis. Excerpta Medica, 1992:279-83.
27. Herrmann F, Cannistra SA, Lindemann A, Blohm D, Rambaldi A, Mertelsmann RH, et al. Functional consequences of monocyte 1L-2 receptor expression. Induction of IL-1β secretion by IFNγ and IL-2. J Immunol 1989;142:139-43.
28. Musso T, Espinoza-Delgado I, Pulkki K, Gusella GL, Longo DL, Varesio L. IL-2 induces IL-6 production in human monocytes. J Immunol 1992;148:795-800.
29. Djeu JY, Liu JH, Wei S, Rui H, Pearson CA, Leonard WJ, et al. Function associated with IL-2 receptor-β on human neutrophils. J Immunol 1993;150:960-70.
30. Zemel D, Imholz ALT, de Waart DR, Dinkla C, Struijk DG, Krediet RT. Appearance of tumor necrosis factor-α and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994;46:1422-30.
31. Carrosi S. Cytokine disordes in CAPD. In: Ota K, Maher J, Winchester J, Hirszel P, editors. Current concepts in peritoneal dialysis. Excerpta Medica, 1992:235-43.